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Abstract
Background: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene
expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze
the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population
originated or resident in the North of Morocco.
Methods: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010
and January 2015. Clinicopathologic and prognostic features have been analyzed. Disease-Free Survival (DFS) and
Overall Survival (OS) have been estimated.
Results: Of all cases, forty-nine (17.6 %) were identified as having triple negative breast cancer with a median age of
46 years. The average tumor size was 3.6 cm. The majority of patients have had invasive ductal carcinoma (91.8 %) and
40.4 % of them were grade III SBR. Nodal metastasis was detected in 38.9 % of the patients and vascular invasion was
found in 36.6 % of them. About half of the patients had an early disease (53.1 %) and 46.9 % were diagnosed at an
advanced stage. Patients with operable tumors (61.2 %) underwent primary surgery and adjuvant chemotherapy.
Patients with no operable tumors (26.5 %) received neoadjuvant chemotherapy followed by surgery, and patients
with metastatic disease (12.2 %) were treated by palliative chemotherapy. DFS and OS at 5 years were respectively
83.7 and 71.4 %. Among 49, twelve had recurrences, found either when diagnosing them or after a follow-up. Local
relapse was 6.1 %. Lung and liver metastases accounted consecutively for 8.2 and 10.2 %. Bone metastases were
found in 4.1 % and brain metastases in 2.1 % of the cases.
Conclusion: Our results are in accordance with literature data, particularly what concerning young age and poor
prognosis among TNBC phenotype. Therefore, the identification of BRCA mutations in our population seems to be
essential in order to better adapt management options for this aggressive form of breast cancer.
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Background
Breast cancer is a heterogeneous disease encompassing
various clinical, morphological and molecular distinct
subtypes. In the early 2000s, through RNA expression pro-
file analysis of breast cancer, Perou and Sorlie have iden-
tified five main molecular subtypes: Luminal A, Luminal
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B, ERBB2, Basal-Like (BL) and Normal-Like (NL), bring-
ing out a new classification of this disease and identifying
groups with distinct biology and prognosis [1].
In clinical practice, BL tumors are often treated as
triple negative breast cancers (TNBCs), tumors which are
defined using immunohistochemical methods. TNBCs
are characterized by lack of expression of hormone recep-
tors (HR, Estrogen ER and Progesterone PR) and human
epidermal growth factor receptor 2 (HER2). This breast
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cancer phenotype accounts for approximately 17 % in
most published series (10 ∼ 20 %) [2–4].
TNBC is over-represented among non-menopausal
African descent women and is characterized by a high
BRCA mutation rate [2, 5–8]. Patients with TNBC are
more likely to experience relapse within the first 3 years
and are at high risk of death in the first 5 years following
diagnosis. Furthermore, TNBC exhibits a high frequency
of metastasis compared to other breast cancer phenotypes
with distinct metastatic patterns, particularly in visceral
and cerebral sites [3, 9–12].
We present here the first study aiming to analyze clin-
icopathologic and prognostic features of triple negative
breast cancer in aMediterranean population originated or
resident in the North of Morocco.
Methods
Patients
We describe a retrospective study of breast cancer in a
Mediterranean population originated or resident in the
North of Morocco. This population represent 10.5 % of
the total Moroccan population. After reviewing data of
the Oncology Clinic Al Amal of Tangier, a total of 279
breast cancer cases was registered between January 2010
and January 2015. In this work only patients diagnosed
with TNBC were recruited.
Methods
Estrogen and progesterone receptors were evaluated on
fixed and paraffin-embedded tissue using immunohisto-
chemical methods. The threshold set out for HR neg-
ativity was a lack (< 1 % positivity) of any ER and
PR immunoreactivity. HER2 was considered negative if
immunohistochemical stains were reported 0, 1+ or if
HER2 FISH showed no gene amplification.
All tumors were classified following histological classifi-
cation (WHO 2003). Histological grading was performed
using Scarff-Bloom-Richardson classification (SBR) as
modified by Elston-Ellis (mSBR). Tumors were classi-
fied according to the TNM system 2010 and regrouped
into American Joint Committee on Cancer stages (AJCC
2010).
Disease-Free Survival (DFS) and Overall Survival (OS)
were assessed using Kaplan-Meier analysis [13]. DFS was
determined from the time of diagnosis to the date of
tumor relapse or last follow-up. OS was defined as the
time between date of diagnosis and death or last follow-
up. Survival according to AJCC stages was also estimated,
early (I, II) and advanced (III, IV) stages. The Log-Rank
test was used to examine the statistical significance of the
differences observed between the two groups early and
advanced. This test was performed at a 5 % level.
Participants provide written informed consent. Ethic
approval for the study was obtained through the Ethics
Committee for Biomedical Research in the Faculty of
Medicine and Pharmacy of Rabat (CERB).
Results
Among 279 patients diagnosed with breast cancer, forty-
nine (17.6 %) were identified as triple negative. The
median age at diagnosis was 46 and was ranging from 28
to 90 years. Approximately two thirds of patients (63.6 %)
were non-menopausal and 24.4 % had a family history of
breast cancer. The main ethnic groups of our population
are Arabs (69.4 %) and Amazigh (26.6 %). Europeans and
sub-Saharan represent only 2 % each.
The average tumor size was 3.6 cm. The overwhelm-
ing majority of patients (91.8 %) had an infiltrating ductal
carcinoma, and 8.2 % of cases had infiltrating lobular car-
cinoma. High-grade tumors represented 40.4 % of cases,
the intermediate 55.3 % and low-grade was only 4.3 %.
Regarding lymph node involvement, 38.9 % of patients had
positive lymph nodes at initial diagnosis and a lympho-
vascular invasion was found in 36.6 % of cases. Patients
with stage I accounted for 12.2 %, stage II (40.8 %), stage
III (34.7 %) and 12.2 % had metastatic disease (stage
IV)(Table 1).
Patients with operable tumors (T1–T2–T3, N0–N1)
which represent 61.2 % in our series, underwent pri-
mary surgery and adjuvant chemotherapy. Patients with
no operable tumors (T4, N2–N3) (26.5 %) received neoad-
juvant chemotherapy followed by surgery. Metastatic can-
cers (12.2 %) received palliative chemotherapy. Breast-
conserving surgery was performed in 31.6 % of cases,
either immediately or after neoadjuvant chemotherapy
(Table 2).
The majority of patients received radiotherapy (70.7 %).
Patients who underwent breast-conserving surgery, breast
irradiation was systematically performed in negative
lymph nodes cases (77.8 %). For patients with lymph
nodes metastasis, nodal irradiation was constantly indi-
cated (22.2 %). About patients who underwent radi-
cal surgery, chest wall irradiation was applied in the
absence of lymph node invasion, at 64.7 % consider-
ing the TN status as a poor prognostic factor indicating
radiotherapy. Chest wall and nodal complete irradiation
was performed for patients who have positive lymph
nodes (35.3 %).
Five years disease-free survival for patients with local-
ized disease was 83.7 %. The overall 5 years survival for
all patients was 71.4 % (Table 3, Figs. 1 and 2). Patients
diagnosed in an advanced stage had shorter survival rate
than those diagnosed at early stage (47.8 % versus 92.3 %
consecutively, with pvalue = 0.002 < 0.05 (Table 3,
Fig. 3)).
Among 49 patients, 12 had recurrence either at diag-
nosis or after follow-up. In this group, local recurrence
was 6.1 %. The distribution of metastatic sites was as
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Table 1 Clinicopathologic characteristics of the population study
Variable Frequency
TNBC 17.6 %


















Invasive ductalcarcinoma 91.8 %






























Table 2 Treatment modalities for all patients
Surgery









following: lung (8.2 %), liver (10.2 %), bone (4.1 %) and
brain (2.1 %)(Table 1).
Discussion
Triple negative breast cancer frequency reported in
the present work (17.6 %) is consistent with national
[14, 15] and international data [2–4]. This frequency
varies according to race/ethnicity and positivity threshold
set out for HR and HER2 expression [2, 16, 17]. Morocco
is a country of northwestern Africa whose population
is characterized by ethnic diversity. Arab and Amazigh
present the majority of this population that contain also
other groups as Jewish, European and sub-Saharan. Eth-
nic composition of our series bears a great resemblance to
that of the whole country. Arab and Amazigh are predom-
inant (96 %). As our case-series is limited, we can not give
any conclusion about TNBC distribution. Furthermore, to
the best of our knowledge, there is no data about TNBC
frequency among these ethnic groups.
TNBC occurs more frequently at a younger age, often
before menopause compared with other breast cancer
subtypes [3]. In the current study, the median age was
46 years and the majority of our patients were non-
menopausal (63.6 %). Early age of onset for breast cancer
can reflect a genetic predisposition in particular muta-
tions of BRCA1 and BRCA2 genes. A strong correlation
has been described between the BRCA pathway and triple
negative breast cancers. The prevalence of germlinemuta-
tions in BRCA genes among triple negative patients varies
between 9 and 20 % [18–21].
Table 3 Outcome of the triple negative group
Kaplan-Meier survival result
Disease free survival 83.7 %
Overall survival at 5 years 71.4 %
Early 92.3 %
Advanced 47.8 %
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Fig. 1 Overall survival at 5 years for all patients
Although somatic mutations in BRCA1 gene repre-
sent about 40 %, there is a highly dysfunction in BRCA1
within tumor cells by other mechanisms, notably epige-
netic modifications like gene methylation [20, 22–24].
Inactivation of BRCA1 gene, which is commonly
described between BRCA1mutations carriers and TNBC,
is responsible for a dysfunction of DNA repair. Hence, this
pathway could be exploited therapeutically by poly (ADP-
ribose) polymerase inhibitors (PARP), repair enzymes for
single strand breaks in DNA, which is the only repair path-
way available currently [25–27]. Besides, this similarity
has nowadays important implications in clinical manage-
ment by genetic testing for germline BRCA1 mutations,
notably in young premenopausal woman, even without
a family history. In the present study, 24.4 % of patients
had a familial history of breast cancer. According to the
Guidelines of National Comprehensive Cancer Network,
Fig. 2 Survival for all patients according to AJCC staging
Fig. 3 Disease-free survival at 5 years for non-metastatic patients
TNBC has become a supplementary individual criterion
for genetic testing. A genetic study of BRCA genes involv-
ing all patients included in this work is ongoing.
Clinically, TN tumors are often large [3]. In this study,
the mean diameter was 3.6 cm. This could be related to
rapid growth of this subtype of tumors and to its relatively
high incidence in young patients who present difficulties
in mammography detection.
The great majority of TN tumors are invasive ductal
carcinomas (Invasive Breast Carcinomas of No Special
Type (NST), WHO classification 2012) with high histo-
logic grade. Interestingly, some TNBCs comprise special
histological subtypes with a favorable prognosis, such as
adenoid cystic carcinoma (called cylindrome) and Juvenile
secretory carcinoma [28, 29]. None of these histological
subtypes was reported in the present study.
Traditionally, as tumor size increases, the rate of lymph
node involvement increases. This correlation was not
observed in our group study. The majority of tumors
(85.7 %) had a diameter superior than 2 cm, paradoxically,
61.1 % of patients were negative for nodal involvement.
These results are consistent with those found in literature
data [3, 30].
Triple negative breast tumors have demonstrated high
chemosensitivity. Such tumors responded in the neoad-
juvant setting and have showed complete pathologic
response (pCR) generally higher than non-TNBCs. This is
the “paradox of TNBC” [31–34].
For patients with inoperable disease (large size, inflam-
matory tumor, etc.), neoadjuvant chemotherapy provides
a means to improve further surgery. Moreover, it gives
the opportunity to propose later, depending on the
quality and the terms of response, a breast-conserving
surgery improving thus the cosmetic and preserving more
women’s body image.
Derkaoui et al. BMCWomen’s Health  (2016) 16:68 Page 5 of 7
Regarding patients with operable disease, neoadjuvant
chemotherapy allows in one hand to test in vivo the treat-
ment effectiveness and to predict pCR rate, which is a
good prognostic factor. On the other hand, it provides
necessary time to genetic testing for BRCA mutations
especially among women aged under 50. This allows guid-
ing management process for mutation carriers. Radical
surgery would be recommended. Preventive measures,
such as prophylactic surgery could be also discussed.
In the present study, the rates of advanced and
metastatic cancers are higher (46.9 and 12.2 % respec-
tively). This is due mainly to lack of early detection in our
population. Therefore, implementation of a national orga-
nized screening program for breast cancer is essential.
The correlation between TN status and increased risk of
local recurrence remains controversial. Some studies did
not show an increased risk. Solin et al. [35] revealed that
local recurrence rate at 8 years was 8 % compared to 4 %
in non-TNBC. Freedman et al. [36] have reported, by ana-
lyzing three groups HR+, HER2 and TN, that the local
recurrence rates at 5 years were similar in the three groups
(2.3, 4.6 and 3.2 % respectively). However in Nguyen et al.
[37] study, the rate of local recurrence at 5 years was sig-
nificantly higher in the TN group compared with Luminal
A and B cancers (7.1 % versus 0.8 % and 1.5 %). In the
present study, the local recurrence rate was 6.1 %.
The TN group presents a significant risk of recurrence
within the first 3 years and death during the 5 years fol-
lowing initial diagnosis [3, 9], the risk of relapse declines
rapidly thereafter. After 8 years of follow up, recurrence is
exceptional [3].
Metastatic progression is characterized by predomi-
nance of visceral sites (notably liver and brain) and lower
incidence of bone metastases [9–12]. In the current study,
we showed a high rate of visceral metastases including
liver (10.2 %) and lungs (8.2 %), but a lower rate of brain
metastases (2.1 %). Bone metastases were found in 4.1 %
of cases.
Prognosis for TN cancers remains pejorative compared
to other subtypes, whether in terms of disease-free sur-
vival or overall survival [2, 3, 38, 39]. DFS and OS at 5
years were respectively 83.7 and 71.4 %. Most recurrences
were recorded in the first 2 to 3 years following diagnosis.
These results are in accordance with literature data [3, 9].
The TNBCs diagnosed at an early stage presented
a five-year survival rate which is strikingly higher
(92.3 %) than advanced TNBCs (47.8 %). Early detec-
tion is therefore one of the most powerful strategies
in reducing cancer mortality and improving chances of
recovery.
Conclusion
The characteristics of TNBC among our population study
are consistent with international literature data, especially
concerning young age at diagnosis, poor prognosis and
pejorative survival. Further research studies for determin-
ing BRCA abnormalities will lead to a better understand-
ing the genetic profile of our population.
The identification of germline BRCAmutations in triple
negative breast tumors seems essential to adapt the ther-
apeutic strategy and to ensure adequate clinical manage-
ment for mutation carriers and their relatives.
At the somatic level, characterization of molecular
defects in triple negative tumors mainly BRCA and p53,
are promising for new targeted therapeutic approaches.
This is the case of PARP inhibitors that target the inacti-
vation of the enzyme poly (ADP-ribose) polymerase, the
only pathway so far available for DNA breaks repair.
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